New trials, regulatory updates, and what the latest studies actually show.
Every Tuesday: one landmark study, one protocol, one regulatory update. Plus new research posts as they publish. Free.
Tirzepatide produces more weight loss. But on cardiovascular events, the head-to-head data shows it ties with semaglutide. Here is what the evidence actually says.
TRIUMPH-1 topline: 28.3% at 80 weeks, 30.3% at 104 weeks. The largest weight loss ever recorded in a Phase 3 trial. Here is what the data shows.
ARA-290 demonstrated structural nerve fiber regeneration in a blinded human trial. The original developer has since closed. Here is what the evidence actually shows.
Six human trials. 900 participants. Positive Phase IIa. Then the pivotal Phase IIb failed at every dose. Development terminated 2007.
Tesamorelin has Phase 3 data from 806 patients showing 15 to 20% visceral fat reduction. The ipamorelin + CJC-1295 stack has zero human body composition trials.
TRIUMPH-4 Phase 3: 28.7% weight loss at 68 weeks. The largest ever in a Phase 3 obesity trial. Seven more readouts coming in 2026.
A dozen compounds are sold for weight loss. Three have Phase 3 data. The rest have failed trials, mouse studies, or nothing at all.
3,400 lawsuits. $2 billion in potential liability. The allegations are about disclosure, not efficacy. Here is what the trial data shows.
SURMOUNT-5 settled it: tirzepatide 20.2% vs semaglutide 13.7% weight loss at 72 weeks. But the real story is in the secondary endpoints.
BPC-157 and TB-500 are routinely combined as the Wolverine Stack. Neither has a controlled human trial for musculoskeletal repair. Here is what the evidence shows.
The most widely used GH secretagogue combination has never been tested in a human RCT. Here is what the evidence shows for each compound and the stack.
TRIUMPH-4 reported 28.7% weight loss at 68 weeks, the largest in any Phase 3 obesity trial. Here is what the data shows and where the hierarchy stands.
Over 500 preclinical publications. Fewer than 30 humans studied. FDA Category 2. BPC-157 is the most researched and least validated peptide we review.